Skip to main content

Guardant Health, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

GH$155.35-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,
2026202520262025
Revenue$360,975$265,196$997,618$700,755
Costs and operating expenses:
Cost of revenue124,82293,587345,690249,515
Research and development expense100,83889,957288,409265,927
Sales and marketing expense177,218127,375536,304351,279
General and administrative expense90,86253,266210,448150,477
Total costs and operating expenses493,740364,1851,380,8511,017,198
Loss from operations(132,765)(98,989)(383,233)(316,443)
Interest income9,7497,39131,09924,063
Interest expense(1,345)(943)(4,038)(2,717)
Other income (expense), net342(48)4937,778
Loss before provision for income taxes(124,019)(92,589)(355,679)(287,319)
Provision for income taxes343136900464
Net loss$(124,362)$(92,725)$(356,579)$(287,783)
Net loss per share, basic and diluted$(0.93)$(0.74)$(2.68)$(2.32)
Weighted-average shares used in computing net loss per share, basic and diluted134,422124,807132,866124,268
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.